26 August 2021 – Notice of Interim Results and Investor Presentation

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Notice of Interim Results and Investor Presentation

Brighton, United Kingdom – 23rd August 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, will announce its Interim Results for the period ended 30th June 2021, on Thursday 9th September 2021.

Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial Officer, will provide a live presentation on the same day, at 09:30 am BST, followed by a Q&A session accessible via the Investor Meet Company platform. The webcast of the presentation will be available on the Company’s investor relations website at www.destinypharma.com.

The presentation is open to analysts and all existing and potential new shareholders. Questions can be submitted pre-event via the Investor Meet Company Dashboard up until 09:00 am BST the day before the meeting, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free, and add to meet Destiny Pharma plc via:

https://www.investormeetcompany.com/destiny-pharma-plc/register-investor

Investors who already follow Destiny Pharma plc on the Investor Meet Company platform will automatically be invited.

-END-

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440

Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 208 078 4357

finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit  www.destinypharma.com

02 August 2021 – Secondary endpoint analysis from Phase 2b trial

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Update on secondary endpoint analysis from recent positive Phase 2b trial

Cardiac surgery patients receiving XF-73 nasal gel exhibited a valuable,
sustained nasal reduction of Staphylococcus aureus

Brighton, United Kingdom, 2nd August 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections is pleased to announce additional, strong data from its recent Phase 2b clinical trial.  In March 2021, the Company announced that this study had met its primary endpoint, demonstrating a highly significant reduction of 2.5 log (>99%) in nasal Staphylococcus aureus immediately prior to surgery compared to placebo (p<0.0001) after just 24 hours of XF-73 nasal gel dosing. The placebo-treated patients showed only a 0.4 log reduction in bacterial load immediately before surgery. All patients in the study also received antibiotic dosing as standard of care.

Today’s additional data shows that XF-73 dosed patients can also benefit from a sustained bacterial reduction at the three post-surgical sample time points after wound closure of 1 hour, 2 and 6 days demonstrating 2.5 log, 2.4 log and 2.8 log reductions, respectively, and sustaining the drop of over 99% in S. aureus nasal burden.  The placebo treated patients reported 0.4 log, 1.5 log and 2.5 log reductions at the same time points. The bacterial reductions in XF-73 treated patients were shown to be highly statistically significant over placebo at the 1 hour and 2 days post-surgery timepoints (p<0.0001 and p<0.003, respectively). As a result of the antibiotic dosing used as standard of care, the 6-day time point reduction in the placebo group were equivalent to the XF-73 arm which was expected as it is known (*Wilson et al, 1977) that pre- and post-surgical systemic anti-staphylococcal antibiotic dosing elicits a slow, gradual reduction in nasal bacterial carriage.

This sustained nasal microbiological effect in the period of greatest risk (pre-surgery to wound healing) of XF-73 in patients is a desirable attribute for the reduction in the risk of acquiring a post-surgical, staphylococcal infection. Today’s new data demonstrates that XF-73 nasal gel has the potential to keep patients at a significantly low S. aureus nasal burden during the period of highest infection risk which runs from 1 hour prior to incision, during surgery itself, to the start of wound healing and out to at least 6 days post-surgery.

Neil Clark, CEO of Destiny Pharma, said:We are very pleased to announce this additional, positive data from the successful Phase 2b study of XF-73 as a novel drug to reduce the incidence of post-surgical infections such as MRSA. We are having discussions with regulators in US and Europe to enable us to design the required Phase 3 clinical study and will announce further updates later in 2021. XF-73 has great potential to provide a safe, fast acting medicine that kills S. aureus in the nose prior to surgery thereby reducing patient infections whilst not generating bacterial resistance. There is a clear clinical need for such a new medicine that helps prevent post-surgical infections and there is a significant commercial opportunity.”

Scientific Advisory Board member, Professor Richard Proctor (Professor Emeritus of Departments of Medical Microbiology & Medicine at University of Wisconsin School of Medicine, Wisconsin, US), said:This new clinical data from the Phase 2b trial wherein XF-73 produces a sustained reduction in nasal burden of S. aureus out to at least 6 days is an important observation for several reasons.  First, nasal S. aureus burden directly correlates with the incidence of post-surgical wound infections.  Second, reduction in S. aureus nasal colonization is associated with decreased numbers of all staphylococcal infections.”

*Wilson et al., In vivo effects of josamycin, erythromycin, and placebo therapy on nasal carriage of Staphylococcus aureus. Antimicrobial Agents and Chemotherapy,1977, 3: p. 407-10)

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440

Optimum Strategic Communications
Mary Clark / Hollie Vile / Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 208 078 4357

finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit  www.destinypharma.com

09 July 2021 – XF-73 Phase 2b data to be presented at ECCMID

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Successful XF-73 nasal gel Phase 2b study data to be presented at 2021 ECCMID Congress

  • Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract

Brighton, United Kingdom – 9th July 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of XF-73 nasal gel will be presented at Europe’s premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) on Saturday, 10 July at 7:35 pm CET

Presentation Title: Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients: preliminary results from a Phase 2 study.

Presenting Author: Julie Mangino MD, FSHEA, FIDSA, Professor Emeritus, Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University College of Medicine, US

Abstract #: 04905

Session: LB: Late breaking clinical trial data

Session code: S182

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit  https://www.destinypharma.com

About ECCMID

ECCMID (https://www.eccmid.org/) is Europe’s premier Clinical Microbiology & Infectious Diseases event, bringing together experts from many fields to present their latest findings, and developments and share their expertise. The scientific programme is built by the ECCMID Programme Committee, and independent group of experts representing all disciplines related to clinical microbiology and infectious diseases.

About XF-73

XF-73 is the lead drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF-73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.

06 July 2021 – NTCD-M3 RD Agreement with US Dept Veterans Affairs

Destiny Pharma plc

(“Destiny Pharma” or “the Company”)

Destiny Pharma and US Department of Veterans Affairs enter into Cooperative Research and Development Agreement to further research NTCD-M3 for prevention of recurrence of Clostridioides difficile infections

Brighton, United Kingdom, 6 July 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, is pleased to announce a Cooperative R&D agreement with the US Department of Veterans Affairs to support studies focusing on identifying new attributes for NTCD-M3, a novel microbiome therapeutic being developed to reduce the recurrence of Clostridioides difficile infections (CDI) in the gut.

Destiny Pharma will collaborate on this research project with the Edward Hines Jr. VA Hospital in Hines, Illinois, utilising their CDI research expertise to complete new preclinical studies that could support the administration of NTCD-M3 to a broader CDI patient population and therefore strengthen the market opportunity. The research project is planned to complete in Q4 2021. Financial terms are not disclosed.

Stuart Johnson, MD Professor of Medicine, Loyola Stritch School of Medicine, will lead the team conducting further studies of NTCD-M3 at the Edward Hines, Jr. VA Hospital, which has long been recognised for its advanced research into the diagnosis, epidemiology, prevention and treatment of CDI.

According to Prof. Johnson, “The potential for prevention of CDI with this non-toxigenic strain of C. difficile has been well-established. However, the mechanism of this protective effect has not been fully established. We are poised to conduct experiments that will help delineate the factors whereby NTCD-M3 prevents infection with toxigenic strains of this ubiquitous pathogen.”

CDI is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year; many of these initial cases then recur leading to 29,000 deaths per year.

NTCD-M3 has the potential to become the leading treatment for CDI prevention, as its Phase 2 data demonstrated a class leading 5% rate of recurrence compared to 30% with placebo.

The benefits of NTCD-M3 include:

  • Single bacterial strain: a naturally occurring, single strain of a non-toxigenic bacteria;
  • Excellent safety profile: well-defined treatment;
  • Strong clinical data: NTCD-M3 recurrence rate of 5% versus 30% with placebo, which is “class leading”;
  • Convenient treatment option: it is complementary to all current standard of care antibiotic treatments, administered as a single capsule once daily for seven days;
  • Well-established manufacturing: will be manufactured at high volume and low cost with a long shelf life which should enable high uptake and a strong pharmacoeconomic position.

Destiny Pharma is progressing the plans for the single Phase 3 clinical study, the design of which has already been discussed with the US FDA, and which needs to be completed before submitting marketing authorisation applications in the US and Europe. The Phase 3 clinical study remains on schedule to commence in 2022.

Destiny Pharma has also commenced discussions with potential licensing partners and collaborators and is encouraged by the level of interest in the programme. The aim is to secure a partner to support the planned Phase 3 clinical study and participate in the future commercial launch of NTCD-M3.

Neil Clark, Chief Executive Officer of Destiny Pharma, said: “We are very pleased to be working with the expert CDI team at the Edward Hines, Jr. VA Hospital in Chicago. The planned study will help Destiny Pharma refine our planning for the NTCD-M3 Phase 3 study that we aim to start in 2022. There is a significant clinical and commercial opportunity for NTCD-M3 as a novel treatment to prevent the recurrence of CDI.”

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
pressoffice@destinypharma.com
+44 (0) 127 370 4440

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
DestinyPharma@optimumcomms.com
+44 (0) 203 174 1789

finnCap Ltd (Nominated Advisor Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 207 220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects.

For further information, please visit www.destinypharma.com

02 July 2021 – Scientific Advisor, Professor Dale Gerding, to chair C. diff. Foundation Symposium

Destiny Pharma plc

(“Destiny Pharma” or “the Company”)

Scientific Advisor Prof Dale Gerding to chair C. diff. Foundation Symposium

Brighton, United Kingdom – 02 July 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, is pleased to announce that its Scientific Advisory Board member, Professor Dale Gerding, a world-leading expert in C. difficile infections (CDI) and the discoverer of NTCD-M3, will be chairing the “C. diff. Patient, Family, and Caregiver” Symposium, to be held virtually on 16 July 2021.

The Symposium, hosted by the C Diff Foundation, will be a gathering of healthcare professionals, practitioners, thought leaders, and C. diff. survivors focused on transforming the patient experience of people living with C. diff. infections worldwide.

Distinguished members and keynote speakers will provide insight on how to identify, evaluate, and prioritize innovations that can quickly touch the lives of patients battling C. diff. infections.

Destiny Pharma’s late-stage asset, NTCD-M3, is a novel microbiome therapeutic being developed to reduce the recurrence of C. diff. infections in the gut. CDI is the leading cause of hospital acquired infection in the US and current treatments lead to significant recurrence. In the US, there are approximately 500,000 cases of CDI each year; many of these initial cases then recur leading to 29,000 deaths per year.

NTCD-M3 has the potential to become the leading treatment for CDI, as it has shown to deliver clear advantages to both existing CDI treatment options and also to those currently in clinical development.

Symposium registration is free of charge and is a live online event. Please register here.

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com 

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com 

About Destiny Pharma plc
Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects. 

For further information on the company, please visit  https://www.destinypharma.com      

29 June 2021 – Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021

Destiny Pharma plc

(“Destiny Pharma” or “the Company”)

Destiny Pharma to present at the Shares and AJ Bell Investor
Webinar on 06 July 2021

Brighton, United Kingdom – 29 June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce that its Chief Executive Officer, Neil Clark, will provide a live presentation on the Company at the Shares and AJ Bell Investor Evening Webinar on Tuesday, 06 July at 6:00 pm BST.

The Shares and AJ Bell Investor Evening Webinar is an opportunity for existing and potential investors to receive a business update from senior executives of listed PLCs.

Attendees will have the opportunity to ask questions to the presenters via an online chat window during the webinar.

Shareholders and potential investors can register to join the webinar for free at:
https://www.sharesmagazine.co.uk/events/event/shares-investor-evening–webinar-060721

-ENDS-

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Hollie Vile/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

About Destiny Pharma plc
Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US, and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of postsurgical staphylococcal hospital infections including MRSA. It is also codeveloping
SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit https://www.destinypharma.com

10 June 2021 – XF-73 data abstract to be presented at 2021 ECCMID

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress

  • XF-73 met its primary end point with >99% nasal aureus reduction within 24 hours
  • Excellent clinical safety profile for XF-73 dosed in patients scheduled for cardiac surgery
  • Infection prevention expert, Professor Julie Mangino MD to present XF-73 data abstract

Brighton, United Kingdom – 10th June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines to prevent life-threatening infections, today announces that an abstract providing analysis and discussion of the late-breaking data arising from the recently completed Phase 2b clinical study of  XF-73 nasal gel has been accepted for presentation at Europe’s premier antimicrobials congress, the 31st European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), to be held 9 – 12 July, 2021.

Presentation Title: Repeated doses of exeporfinium chloride (XF-73) nasal gel over 24 hours significantly reduced the burden of Staphylococcus aureus nasal carriage in at-risk surgical patients: preliminary results from a Phase 2 study. The presentation will update the audience on the following highlights:

  • Met primary endpoint: XF-73 reduced the mean nasal burden of S. aureus in patients undergoing open heart surgery by 2.5 log (CFU/ml) in the 24 hours immediately before surgery a highly statistically significant result, (p<0.0001). This equates to a 99.5% reduction in S. aureus bacterial nasal carriage, which is a very effective reduction by accepted clinical measures.
  • XF-73 showed 2.1 log, (>99%), greater reduction than placebo in the same patient population and this difference in reduction of nasal burden of S. aureus was highly statistically significant (p<0.0001). The effect was maintained during surgery, considered the period when the risk for infections is the highest.
  • These positive results were achieved with just three doses of 0.2% (w/w) XF-73 nasal gel in the 24 hours before incision and the start of surgery.
  • There were no XF-73 nasal gel treatment related adverse events.

Presenting Author:  Julie Mangino MD, FSHEA, FIDSA, Professor Emeritus, Department of Internal Medicine, Division of Infectious Diseases, The Ohio State University College of Medicine, US

Abstract #: 04905

Session: LB: Late breaking clinical trial data

Session code: S182

ECCMID (https://www.eccmid.org/) is the world’s premier Clinical Microbiology & Infectious Diseases event, bringing together experts from many fields to present their latest findings, and developments and share their expertise.

XF-73 is the lead drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF-73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.

If you would like to meet with Destiny Pharma, please email us on conferences@destinypharma.com

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma plc

Destiny Pharma is a UK based, clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence, which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections, and has earlier grant funded XF research projects.

For further information on the company, please visit  https://www.destinypharma.com

07 June 2021 – Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance

Highlights the global threat of the “silent pandemic” and the urgent need for the development of new treatments

Brighton, United Kingdom – 7th June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, welcomes the G7 Health Ministers’ Meeting communique on 4 June 2021 and its strong message highlighting the global threat of the “silent pandemic” of Antimicrobial Resistance (AMR) and the urgent need for the development of new treatments. Full details are set out at https://www.g7uk.org/g7-health-ministers-meeting-communique-oxford-4-june-2021/

In the announcement the G7 have set out their clear intention to offer increased government support through regulatory frameworks, financial investment and commercial procurement schemes for new medicines that address AMR. They note that the COVID-19 pandemic has “brought into stark focus the impact a novel and initially untreatable infectious disease can have on humanity … [and] highlighted the importance of infection prevention and control measures to tackle AMR.”

Destiny Pharma has been focused for many years on developing novel medicines from its XF platform that specifically address the AMR threat through the XF platform’s unique mechanism of action which can provide safe, effective and fast acting treatments that
do not generate resitance. Its lead programme, XF-73 nasal gel for the decolonisation of patients prior to surgery who are carrying Staphylococcus aureus in the nose, recently delivered excellent Phase 2 data and will now move forward to its final Phase 3 clinical
trials. There are also earlier XF research projects targeted at preventing and/or treating infections whilst also addressing the threat of AMR and not causing the generation of new “superbug” strains.

Destiny Pharma also has a Phase 3 ready clinical programme targeted at preventing the recurrence of gut infections caused by toxic strains of C. difficile infections (CDI). This programme uses a non-toxic strain of C. difficile called NTCD-M3 and has extensive
Phase 2 data showing it to be very effective at reducing the recurrence of CDI and thereby reduces the need for additional treatment with antibiotics. Lower use of antibiotics has the potential to reduce the generation of resistant strains and is in line with G7 and
WHO recommendations.

Neil Clark, CEO of Destiny Pharma, commented:

“We are very pleased that the G7 Health Ministers Meeting has again strongly supported investment, regulatory and commercial incentives for drug developers such as Destiny Pharma. We are working hard to bring new medicines to patients that address the global threat of AMR whilst at the same time delivering cost effective and safe treatments to patients and healthcare practitioners.

Our XF platform has been targeted at the AMR threat for many years and we are very well positioned to rise to the challenge presented by these dangerous pathogens.”

For further information, please contact:

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com

Optimum Strategic Communications
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma
Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a
novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XFresearch projects.

For further information on the company, please visit https://www.destinypharma.com

03 June 2021 – Result of Annual General Meeting

Destiny Pharma plc
(“Destiny Pharma” or “the Company”)

Result of Annual General Meeting 

Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, announces that all resolutions proposed to shareholders at the Annual General Meeting held earlier today were duly passed.

The full text of each resolution was included in the notice of the meeting, which was made available on the Company’s website and posted to shareholders on 4th May 2021. The results for the resolutions will shortly be available on the Investors section of the Company’s website, www.destinypharma.com.

Nick Rodgers, Chairman of Destiny Pharma, commented:

“It has been a transformational last six months for Destiny Pharma. We recently delivered excellent Phase 2b data from our XF-73 nasal gel clinical study for the prevention of post-surgical infections and have now started talking to regulators regarding possible Phase 3 clinical plans. Also, we expanded our pipeline through the acquisition of NTCD-M3 to take it through its Phase 3 clinical study. NTCD-M3 has the potential to become the leading treatment for C. difficile infections, targeting a market that is forecast to grow to $1.7 billion by 2026. We remain committed to developing our novel products that prevent infections and look forward to delivering further progress and another successful year.”

For further information, please contact: 

Destiny Pharma plc
Neil Clark, CEO
Shaun Claydon, CFO
+44 (0) 1273 704 440
pressoffice@destinypharma.com 

Optimum Strategic Communications 
Mary Clark/ Shabnam Bashir/ Manel Mateus
+44 (0) 203 174 1789
destinypharma@optimumcomms.com 

finnCap Ltd (Nominated Advisor & Joint Broker)
Geoff Nash / Kate Bannatyne, Corporate Finance
Alice Lane, Corporate Broking
+44 (0) 20 7220 0500

WG Partners (Joint Broker)
Nigel Barnes / Claes Spång / Nigel Birks
+44 (0) 203 705 9330

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections. Its pipeline has novel microbiome-based biotherapeutics and XF drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US and also XF-73 nasal gel, which has recently completed a positive Phase 2b clinical trial targeting the prevention of post-surgical staphylococcal hospital infections including MRSA. It is also co-developing SPOR-COV, a novel, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections and has earlier grant funded XF research projects. 

For further information on the company, please visit  https://www.destinypharma.com